Also known as: Jefferies, Jefferies Financial Group
Jefferies is a global full-service investment banking and capital markets firm that provides investment banking, equities, fixed income, research, and wealth management services. The firm emphasizes an entrepreneurial, high-touch culture and serves clients across global markets.
Bio-Techne reported quarterly results ahead of earnings and revenue forecasts, attracting fresh institutional buying. Despite the earnings beat, shares declined 15-20% over 30 days and posted losses over one year.
Summit Therapeutics will participate in three investor conferences in March 2026, following FDA acceptance of its BLA for ivonescimab in lung cancer with a PDUFA date of November 14, 2026.
Two financial services firms raised their price targets for Moderna in mid-February 2026, with RBC Capital increasing its target to $30 and Evercore ISI Group raising its target to $35, both maintaining neutral ratings.
Multiple institutional investors modified their positions in AstraZeneca during the third quarter, with new stakes and adjustments reported in SEC filings. The company announced a dividend of $1.595 per share payable March 23rd.
Nektar Therapeutics completed a $460 million public offering on February 13, 2026, selling 7.6 million shares of common stock and pre-funded warrants. The clinical-stage biotechnology company is developing immunotherapy treatments for autoimmune diseases.
